Assessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implant

Basit Öğe Kaydı
dc.authorid0000-0002-8206-781Xen_US
dc.contributor.authorVural, Esra
dc.contributor.authorHazar, Leyla
dc.date.accessioned2022-08-17T10:57:17Z
dc.date.available2022-08-17T10:57:17Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.descriptionWOS:000648054200001
dc.descriptionPMID: 33961524
dc.description.abstractPurpose: To evaluate inflammation biomarkers in diabetic macular edema (DME) treated with intravitreal dexamethasone implant (Ozurdex(R)). Methods: This retrospective single-center study investigated 64 eyes of 64 patients with DME who were nonresponsive to prior antivascular endothelial growth factor and treated with intravitreal Ozurdex. The neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte ratio (MLR), and platelet/lymphocyte ratio were calculated. Visual acuity and optical coherence tomography markers, including hyper-reflective dots and subretinal fluid (SRF), were determined, and central retinal thickness was also evaluated monthly for 3 months. Results: The average age was 64.06 +/- 7.81 (48-84) years. The baseline NLR and MLR were significantly higher in patients with better visual outcomes (P = 0.029 and P = 0.048, respectively). Better anatomical outcomes were observed in the presence of SRF (P = 0.027). No significant differences were observed in the rates of the presence of SRF and hyper-reflective points about the better functional outcome (P > 0.05). Conclusions: SRF as an imaging biomarker, and NLR and MLR as blood biomarkers, stand out as markers of inflammation and were found to be associated with better response to Ozurdex implantation in DME.en_US
dc.identifier.citationVural, E. ve Hazar, L. (2021). Assessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implant. Journal of Ocular Pharmacology and Therapeutics, 37(7), 430-437. https://doi.org/10.1089/jop.2020.0130en_US
dc.identifier.doi10.1089/jop.2020.0130
dc.identifier.endpage437en_US
dc.identifier.issn1080-7683
dc.identifier.issn1557-7732
dc.identifier.issue7en_US
dc.identifier.pmid33961524
dc.identifier.scopus2-s2.0-85114887728
dc.identifier.scopusqualityQ1
dc.identifier.startpage430en_US
dc.identifier.urihttps://www.liebertpub.com/doi/pdf/10.1089/jop.2020.0130?download=true
dc.identifier.urihttps://hdl.handle.net/11468/10187
dc.identifier.volume37en_US
dc.identifier.wosWOS:000648054200001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorHazar, Leyla
dc.language.isoenen_US
dc.publisherMary Ann Liebert, INCen_US
dc.relation.ispartofJournal of Ocular Pharmacology and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiomarkeren_US
dc.subjectInflammationen_US
dc.subjectHyper-reflective dotsen_US
dc.subjectNeutrophilen_US
dc.subjectLymphocyte ratioen_US
dc.subjectDiabetic macular edemaen_US
dc.titleAssessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implanten_US
dc.titleAssessment of inflammation biomarkers in diabetic macular edema treated with intravitreal dexamethasone implant
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Cerrahi Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu